Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of JTT-251 in heart failure with reduced ejection fraction
NL-OMON48915Phase 2Withdrawn
- Sponsor
- Akros Pharma Inc.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JTT-251 in heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Akros Pharma Inc. Primary endpoints: Change from baseline to end of treatment in left ventricular ejection fraction, Change from baseline to end of treatment in left ventricular end-systolic volume index and 4 more. Planned start Dec 2018; status: withdrawn.
02
Drugs
JTT-251
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON48915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48915.